Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : HFB30132A
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : HiFiBiO Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
HiFiBiO, Pharmsynthez and IBCh Sign Covid-19 Antibody Development Deal
Details : The partnership aims to advance HFB30132A, a SARS-CoV-2 neutralizing antibody for the treatment of COVID-19, through clinical development and commercial sale in Russia, pending approval from the Ministry of Health of the Russian Federation.
Brand Name : HFB30132A
Molecule Type : Large molecule
Upfront Cash : Undisclosed
November 23, 2020
Lead Product(s) : HFB30132A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : HiFiBiO Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?